Iain Dukes - Iovance Biotherapeutics Chairman of the Board
| IOVA Stock | USD 11.31 0.41 3.50% |
Chairman
Dr. Iain Dukes D.Phil. serves as Chairman of the Board of the company. Dr. Dukes joined our Board of Directors on August 4, 2016 and was appointed Chairman of the Board on August 16, 2016. Dr. Dukes currently is a Venture Partner at OrbiMed Advisors LLC. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories through May 2016. He joined Merck in August 2013. Prior to joining Merck, Dr. Dukes was Vice President of External Research Development at Amgen, from August 2010 to August 2013. From 2007 to 2010, Dr. Dukes was the President and Chief Executive Officer, and a member of the board of directors, of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. From 2000 to 2007, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, from 1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group since 2016.
| Age | 59 |
| Tenure | 8 years |
| Address | 825 Industrial Road, San Carlos, CA, United States, 94070 |
| Phone | 650 260 7120 |
| Web | https://www.iovance.com |
Iovance Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3986) % which means that it has lost $0.3986 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8191) %, meaning that it created substantial loss on money invested by shareholders. Iovance Biotherapeutics' management efficiency ratios could be used to measure how well Iovance Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.85. In addition to that, Return On Capital Employed is expected to decline to -0.72. At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 496.1 M, whereas Total Current Assets are forecasted to decline to about 218.7 M.Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| William Goolsbee | Sarepta Therapeutics | 60 | |
| Jonathan MD | Ocean Biomedical | 55 | |
| Gary Jacob | Hepion Pharmaceuticals | 70 | |
| Jack MD | Ocean Biomedical | 73 | |
| Allan Jacobson | PTC Therapeutics | 78 | |
| Gerald Chan | Apellis Pharmaceuticals | 66 | |
| Keith Gollust | Madrigal Pharmaceuticals | 72 | |
| Michael Schmertzler | PTC Therapeutics | 66 | |
Management Performance
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.4 |
Iovance Biotherapeutics Leadership Team
Elected by the shareholders, the Iovance Biotherapeutics' board of directors comprises two types of representatives: Iovance Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iovance. The board's role is to monitor Iovance Biotherapeutics' management team and ensure that shareholders' interests are well served. Iovance Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iovance Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Weiser, Independent Director | ||
| Friedrich MD, Chief Officer | ||
| JeanMarc MBA, Chief Officer | ||
| Sara Pellegrino, Vice Relations | ||
| Madan Jagasia, Ex Affairs | ||
| Tracy Winton, Senior Resources | ||
| Frederick Vogt, General Counsel | ||
| Brian MBA, Senior Technology | ||
| Timothy Morris, CFO, Secretary | ||
| Solebury Trout, IR Contact Officer | ||
| James MBA, Executive Commercial | ||
| Sarah McCabe, IR Contact Officer | ||
| Esq JD, President, CEO | ||
| Sanford Hillsberg, Independent Director | ||
| Igor Bilinsky, Chief Officer | ||
| Maria Fardis, President CEO, Director | ||
| Wayne Rothbaum, Independent Director | ||
| Merrill McPeak, Independent Director | ||
| Howard MBA, Chief Officer | ||
| Athena Countouriotis, Director | ||
| Iain Dukes, Chairman of the Board | ||
| Ryan Maynard, Independent Director | ||
| Friedrich Finckenstein, Chief Medical Officer |
Iovance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Iovance Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (251.57) % | ||||
| Current Valuation | 3.09 B | ||||
| Shares Outstanding | 279.31 M | ||||
| Shares Owned By Insiders | 0.56 % | ||||
| Shares Owned By Institutions | 89.20 % | ||||
| Number Of Shares Shorted | 46.38 M | ||||
| Price To Earning | (3.51) X | ||||
| Price To Book | 5.90 X |
Iovance Biotherapeutics Investors Sentiment
The influence of Iovance Biotherapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Iovance. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Iovance Biotherapeutics' public news can be used to forecast risks associated with an investment in Iovance. The trend in average sentiment can be used to explain how an investor holding Iovance can time the market purely based on public headlines and social activities around Iovance Biotherapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Iovance Biotherapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Iovance Biotherapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Iovance Biotherapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Iovance Biotherapeutics.
Iovance Biotherapeutics Implied Volatility | 164.55 |
Iovance Biotherapeutics' implied volatility exposes the market's sentiment of Iovance Biotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Iovance Biotherapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Iovance Biotherapeutics stock will not fluctuate a lot when Iovance Biotherapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Iovance Biotherapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Iovance Biotherapeutics' short interest history, or implied volatility extrapolated from Iovance Biotherapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Iovance Stock analysis
When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Iovance Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Revenue Per Share 0.005 | Return On Assets (0.40) | Return On Equity (0.82) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.